Kudos on your GERN trade.
I am only worth listening to when it concerns the ophthalmic arena -- (idiot savant here)
This market looks very vulnerable overall.
I have lightened up quite a bit in energy E+Ps.
Thx. GERN pulling back as as abstract is analyed closer. Evidently analysts are noticing that GERN was somewhat liberal in their definition of Complete Response compared to accepted definitions. Regardless, it sounds like good data, maybe just not GREAT data. GERN will now be a battleground stock like SRPT who thinks using trail data from 7 'good' patients out of a 9 patient PhII trial is enough for FDA approval.
That begs the question of whether OHRP is truly a crash/homerun on PhII data. Maybe Livermore's hypothothese on Squalamine reaching back of eye will hold somewhat true giving some benefit, but not overwhelming. Then what does OHRP stock do?
Whatever way it goes, I'm guessing this board won't be the same after the Squalamine PhII data is released.